George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1075
Bid: 0.105
Ask: 0.11
Change: 0.00125 (1.18%)
Spread: 0.005 (4.762%)
Open: 0.10625
High: 0.00
Low: 0.00
Prev. Close: 0.10625
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

30 Oct 2023 11:52

RNS Number : 7331R
Versarien PLC
30 October 2023
 

30 October 2023

Versarien Plc

("Versarien" or the "Company")

Result of General Meeting

Versarien Plc (AIM: VRS), the advanced materials engineering group, is pleased to confirm that at the Company's General Meeting held earlier today, all resolutions were duly passed. Full details of the resolutions are set out in the Notice of General Meeting dated 12 October 2023 and available on the Company's website at: https://www.versarien.com/investors/reports-and-presentations/

The proxy votes cast were as follows:

Resolution

For

 

Against

 

Abstain

1 - to sub-divide the Existing Ordinary Shares into New Ordinary Shares and Deferred Shares

 

23,267,848

96.07%

951,505

3.93%

645,931

2 - to alter the Articles to allow for the issue of New Deferred Shares

 

23,260,834

95.77%

1,027,547

4.23%

576,903

3 - to authorise the Directors to allot shares in the Company

 

22,845,045

95.73%

1,019,150

4.27%

1,001,089

4 - to disapply statutory pre-emption rights

 

22,609,443

94.75%

1,253,097

5.25%

1,002,744

 

Share Capital Reorganisation

Following the passing of the resolutions at the General Meeting, each of the Company's 330,779,690 Existing Ordinary Shares will be sub-divided into one New Ordinary Share of 0.1p (the "New Ordinary Shares") and one deferred share of 0.9p ("New Deferred Shares"). The New Deferred Shares will have little economic value as they will not carry any rights to vote or dividend rights, although the New Deferred Shares will rank pari passu with the New Ordinary Shares on a return of capital or on a winding up of the Company.

 

Admission to AIM and Total Voting Rights

Dealings on AIM in the Existing Ordinary Shares is expected to cease at the close of business on 30 October 2023. Application has been made for the admission of 330,779,690 New Ordinary Shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading in the New Ordinary Shares will commence at 8.00 a.m. on or around 31 October 2023. No application will be made for admission of the New Deferred Shares to trading on AIM nor will any such application be made to any other exchange.

Following Admission, there will be a total of 330,779,690 New Ordinary Shares, with voting rights, in issue. The Company does not hold any shares in treasury. Consequently, 330,779,690 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise indicated, all defined terms in this announcement shall have the same meaning as described in the Company's announcement dated 12 October 2023 and the Circular which was posted to shareholders on the same day.

 

 

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

 

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

For further information please see: http://www.versarien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMWPGGAUUPWGGU
Date   Source Headline
28th Mar 20247:00 amRNSAudited Results for year ended 30 September 2023
28th Mar 20247:00 amRNSTotal Voting Rights
20th Mar 20248:33 amRNSPlacing to raise £615,000
14th Mar 20247:00 amRNSSouth American Graphinks Agreements
11th Mar 20247:00 amRNSSale of Korean Assets and Licencing of IP
16th Feb 20242:22 pmRNSNotification of final results
7th Feb 20247:00 amRNSReceipt of Legal Claims
31st Jan 20247:00 amRNSTotal Voting Rights
23rd Jan 20244:53 pmRNSHolding(s) in Company
23rd Jan 20241:24 pmRNSHolding(s) in Company
19th Jan 20247:00 amRNSPlacing to raise £400,000
10th Jan 202411:29 amRNSResult of General Meeting
20th Dec 20237:00 amRNSCompany Update and Notice of General Meeting
30th Nov 20237:00 amRNSTotal Voting Rights
8th Nov 20237:00 amRNSPlacing to raise £454,822
30th Oct 202311:52 amRNSResult of General Meeting
30th Oct 20237:00 amRNSGeneral Meeting Statement
12th Oct 20237:00 amRNSNotice of General Meeting
2nd Oct 20237:00 amRNSCorporate Update
13th Sep 20237:00 amRNSTurnaround Strategy - Gnanomat Grant Award
31st Jul 20237:00 amRNSTotal Voting Rights
18th Jul 20234:31 pmRNSDirectorate Changes
14th Jul 20237:00 amRNSPlacing to raise £650,000
4th Jul 202310:54 amRNSResult of General Meeting
4th Jul 20237:00 amRNSGeneral Meeting Statement
15th Jun 20237:00 amRNSNotice of General Meeting
9th Jun 20237:00 amRNSInterim Results
31st May 20237:00 amRNSTotal Voting Rights
17th May 20237:00 amRNSSuccessful Cementene precast concrete trials
3rd May 20239:30 amRNSPlacing and Update on Turnaround Strategy
31st Mar 20237:00 amRNSTotal Voting Rights
29th Mar 202311:22 amRNSResult of AGM
29th Mar 20237:00 amRNSAGM Statement
15th Mar 20237:00 amRNSPlacing to raise £318,000
14th Mar 20232:56 pmRNSFurther re Resignation of Chief Executive Officer
10th Mar 20237:00 amRNSResignation of Chief Executive Officer
6th Mar 20237:00 amRNSCostain Civil Engineering Project
1st Mar 202312:00 pmRNSUmbro Launch
28th Feb 20237:00 amRNSNotice of AGM and Posting of Annual Report
21st Feb 20237:00 amRNSResults for the 18 months ended 30 September 2022
9th Feb 20238:33 amRNSAIM Rule 17 Update
27th Jan 20237:00 amRNSGraphene-Wear OEKO-TEX Eco Passport certification
24th Jan 20231:56 pmRNSFinal Results Update
30th Dec 20227:00 amRNSTotal Voting Rights
6th Dec 20229:40 amRNSPlacing to raise £1.85 million
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSG-SCALE Update & Innovate UK Loan Variation
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.